Pfizer (PFE) Stock Price, Chart, Company Profile & AI Analysis

Key Takeaways

• Pfizer shares have gained roughly 10% over the last 30 days, climbing from about $27.80 to around $30.60.
• Third-quarter 2026 results topped consensus, with revenue of $16.58 billion and adjusted EPS of $0.87, and the company raised its full-year 2026 guidance.
• Non-COVID revenue rose 7% operationally, while sales of launched and acquired products jumped 32%, offsetting fading COVID-19 product sales.
• Over the past three months the stock has advanced more than 20%, and it is up roughly 23% year-to-date.
• The advance reflects improving sentiment around Pfizer's oncology franchise, obesity pipeline, and cost-realignment initiatives.
• For deeper analysis, review Pfizer's Price Targets, Earnings, and Forecast pages.
• Discover top-performing automated strategies on Trending AI Robots.

Pfizer (PFE) Company Overview and Market Position

Pfizer Inc. is one of the world's largest pharmaceutical companies, developing, manufacturing, and marketing medicines and vaccines across primary care, specialty care, and oncology. Its portfolio includes blood thinner Eliquis, pneumococcal vaccine Prevnar, transthyretin amyloidosis treatment Vyndaqel, and cancer medicines such as Padcev, which came through Pfizer's acquisition of Seagen. Investors follow the stock for its diversified revenue base, dividend, and ongoing effort to offset post-pandemic revenue declines and upcoming patent expirations through new product launches, acquisitions, and disciplined cost management.

Pfizer (PFE) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, PFE has risen from roughly $27.80 to about $30.60, an increase of approximately 10%. The shares dipped near $27.40 in early October before steadily recovering, with the advance accelerating into the company's third-quarter earnings release.

The move is part of a longer recovery. Over the past quarter, the stock has climbed from about $25.00 in early August to around $30.60, a gain of more than 20%. The shares are up roughly 23% year-to-date and have traded near their highest levels since mid-2024.

What Drove PFE Stock Price in the Last 30 Days

The strongest catalyst was Pfizer's third-quarter 2026 report. The company posted revenue of $16.58 billion, above consensus estimates near $15.9 billion, and adjusted EPS of $0.87 versus expectations of about $0.73. Management raised full-year revenue guidance to $62 billion–$64 billion, up from $60.5 billion–$62.5 billion, and lifted adjusted EPS guidance to $2.95–$3.05 from $2.80–$3.00.

Beneath the headline figures, non-COVID revenue grew 7% operationally, and launched and acquired products rose 32% operationally, reflecting strength in Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena. Those gains helped offset a 63% decline in Paxlovid sales and a 29% decline in Comirnaty revenue. The period also featured a positive Phase 3 readout for Elrexfio (elranatamab) in relapsed or refractory multiple myeloma, and the company named Cecile Guegan as permanent CFO.

Broader sector sentiment provided additional support. In the same window, peers including Eli Lilly (LLY), Merck (MRK), and Bristol Myers Squibb (BMY) also reported results ahead of expectations and raised guidance, lifting healthcare names even as momentum shifted away from parts of the technology sector.

What Drove PFE Stock Performance Over the Last Quarter

The three-month advance reflects a broader reassessment of Pfizer's post-pandemic growth story. As COVID-related sales normalize, investors have focused on the company's oncology franchise, led by the Seagen portfolio, and its push into obesity treatments following the Metsera acquisition, which added experimental therapies including a once-monthly injectable. The company is also executing a cost-realignment program targeting roughly $9.7 billion in cumulative net savings through 2029, which management says should protect margins as older products lose exclusivity. This narrative, combined with a dividend yield above 5% and a comparatively modest valuation, has helped the stock recover from its multi-year lows.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of tickers, but only the most relevant and highest-performing robots appear in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing investors to browse approaches suited to different risk profiles and holding periods. Reviewing the page can help traders compare automated strategies and identify tools that align with their own research process.

PFE Stock Forecast Drivers: What Investors Should Watch Next

Investors will monitor whether Pfizer can sustain its non-COVID growth momentum and deliver on its upgraded 2026 guidance. Key factors include the trajectory of Eliquis revenue as Medicare-negotiated pricing takes effect, progress of the obesity and oncology pipelines, and the financial impact of the Innovent Biologics collaboration. Upcoming patent expirations for products such as Eliquis and Ibrance, execution of the cost-savings program, and broader pharmaceutical pricing and regulatory developments are also likely to shape sentiment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations